Treatment-resistant depression pipeline, 2026 mid-year reference
Reference layout of the treatment-resistant depression pipeline as of mid-2026: approved mechanisms, late-stage assets, the psychedelic and ketamine-class programs, novel non-monoamine mechanisms, and the live commercial questions across the pipeline.
Reference layout of the treatment-resistant depression pipeline as of mid-2026. Includes approved mechanisms, late-stage assets, the psychedelic and ketamine-class programs, novel non-monoamine mechanisms, and the live commercial questions. Useful as a quick orientation for cross-functional teams entering the TRD conversation as the commercial frame evolves from monoamine-mechanism dominance to a multi-mechanism conversation in which sequencing and patient-profile matching are the differentiators.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.